Open Access<p>Arginine-Modified Polymers Facilitate Poly (Lactide-Co-Glycolide)-Based Nanoparticle Gene Delivery to Primary Human Astrocytes</p>
Author(s) -
Jessica Proulx,
Chaitanya R. Joshi,
Sivakumar Vijayaraghavalu,
Manju Saraswathy,
Vinod Labhasetwar,
Anuja Ghorpade,
Kathleen Borgmann
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s250865
Subject(s) - plga , gene delivery , polyethylenimine , cytotoxicity , genetic enhancement , biocompatibility , reporter gene , astrocyte , microbiology and biotechnology , transfection , chemistry , materials science , gene expression , biophysics , nanotechnology , biochemistry , biology , nanoparticle , in vitro , gene , central nervous system , organic chemistry , neuroscience
Astrocyte dysfunction is a hallmark of central nervous system injury or infection. As a primary contributor to neurodegeneration, astrocytes are an ideal therapeutic target to combat neurodegenerative conditions. Gene therapy has arisen as an innovative technique that provides excellent prospect for disease intervention. Poly (lactide-co-glycolide) (PLGA) and polyethylenimine (PEI) are polymeric nanoparticles commonly used in gene delivery, each manifesting their own set of advantages and disadvantages. As a clinically approved polymer by the Federal Drug Administration, well characterized for its biodegradability and biocompatibility, PLGA-based nanoparticles (PLGA-NPs) are appealing for translational gene delivery systems. However, our investigations revealed PLGA-NPs were ineffective at facilitating exogenous gene expression in primary human astrocytes, despite their success in other cell lines. Furthermore, PEI polymers illustrate high delivery efficiency but induce cytotoxicity. The purpose of this study is to develop viable and biocompatible NPsystem for astrocyte-targeted gene therapy.